Clinical article · Acute care, Specialties, Medicines and results

Stevens-Johnson syndrome and TEN: early recognition, SCORTEN and the first 24 hours

Written for
Hospital physicians, emergency doctors and residents
Reading time
7 minutes
Published
Updated

Written by the Sana Health team for clinicians. It summarises published guidance, is not a guideline and has not been peer reviewed. Check current local protocols before acting.

Key points

  • Fever with painful dusky skin and erosions at two or more mucosal sites is SJS or TEN until proved otherwise.
  • The culprit drug is identified with a dated timeline and stopped at once; early withdrawal is the one intervention everyone agrees on.
  • SCORTEN, calculated in the first 24 hours and again around day 3, estimates mortality and supports the decision on burns-unit or intensive care.
  • Best supportive care in an experienced centre is the cornerstone of treatment; the evidence for systemic immunomodulating therapy is uncertain.
  • Ophthalmology review is needed early, because eye involvement is common and can cause permanent visual loss.

Recognise it early

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are delayed-type hypersensitivity reactions, usually to a drug, and true medical emergencies [1, 2]. They form one disease, separated by the area of skin detached: under 10% of body surface area in SJS, 10% to 30% in SJS/TEN overlap, and over 30% in TEN [2, 3]. Erythema multiforme major, usually triggered by infection, is a different condition [3].

  • A prodrome of fever, malaise, sore throat and sore eyes, often before any rash.
  • Painful, dusky or purpuric macules and atypical flat targets, typically starting on the trunk and face, which blister and slough.
  • Erosions at two or more mucosal sites: mouth and lips, conjunctivae, genitals.
  • Skin pain out of proportion to the appearance, and a positive Nikolsky sign.
  • On darker skin, early lesions may look violaceous, grey or dark brown rather than red.

The main differentials are erythema multiforme major, staphylococcal scalded skin syndrome, acute generalised exanthematous pustulosis, DRESS, generalised bullous fixed drug eruption, linear IgA disease and other autoimmune blistering disorders. A skin biopsy showing full-thickness epidermal necrosis, with a sample for direct immunofluorescence, helps to separate them.

Find and stop the culprit

Early withdrawal of the culprit drug is mandatory [1]. The useful tool is a dated timeline of every medicine started in the previous 8 weeks, including over-the-counter, herbal and traditional products. SJS and TEN usually begin within about 4 to 28 days of starting the responsible drug; a drug started the day before, or taken safely for months, is less likely to be the cause. Algorithms for drug causality, such as ALDEN, formalise this reasoning.

  • Frequent culprits include allopurinol, carbamazepine, lamotrigine, phenytoin and phenobarbital, sulfonamide antibiotics such as co-trimoxazole, nevirapine and oxicam NSAIDs.
  • Antibiotics are an important cause worldwide, and a meta-analysis has described their contribution across regions [9].
  • Genetic risk matters: the HLA-B*15:02 allele and carbamazepine-induced SJS and TEN have been studied in a meta-analysis, and screening before carbamazepine is recommended for patients of some Asian ancestries [8].
  • In children, Mycoplasma pneumoniae infection can cause a similar mucositis-predominant picture.

Stop every non-essential drug when the culprit is uncertain, and record the reaction prominently in the patient's notes and allergy record.

SCORTEN

SCORTEN is the most widely used severity score and predicts mortality [7]. Each item scores one point; it is calculated in the first 24 hours and repeated around day 3, as the UK guideline advises [5].

SCORTEN itemScores 1 point when
Age40 years or older
MalignancyPresent
Heart rate120 per minute or more
Body surface area detachedMore than 10% on day 1
Serum ureaAbove 10 mmol/L
Serum glucoseAbove 14 mmol/L
Serum bicarbonateBelow 20 mmol/L

Predicted mortality rises steeply with each point. The score supports, but does not replace, the clinical decision on where the patient should be cared for: a patient with extensive detachment needs a burns unit or intensive care whatever the total.

The first 24 hours

In the acute phase, best supportive care in an experienced centre is the cornerstone of treatment [4], and supportive care guidelines set out its components [5, 6].

  1. Stop the culprit and arrange transfer to a burns unit or intensive care unit with dermatology input, particularly when more than 10% of the skin is detached.
  2. Nurse in a warm side room with barrier precautions, on a pressure-relieving surface, with non-adherent dressings and gentle handling of the skin.
  3. Give intravenous fluids guided by urine output and haemodynamics; requirements are usually lower than burns formulas suggest.
  4. Provide analgesia, nutrition, mouth care, urogenital care and thromboprophylaxis, and monitor electrolytes and glucose.
  5. Take swabs from the skin and mucosae, and treat infection when it appears rather than giving prophylactic antibiotics.
  6. Arrange ophthalmology review within 24 hours.

Eye involvement occurs in roughly half to two thirds of patients and can lead to permanent visual loss, so regular ophthalmic care in the acute phase is essential [10]. Systemic treatments, including corticosteroids, intravenous immunoglobulin, ciclosporin and etanercept, have been studied, but the evidence for their effect on mortality remains uncertain [11, 12]. Decisions about them are made with the specialist team.

After the acute phase

Survivors often have long-term problems: ocular surface disease, scarring of mucosae, nail and pigment changes, and psychological effects. Follow-up should be planned with dermatology and ophthalmology. The patient should be told the name of the culprit drug and of related drugs to avoid, and given written confirmation. Reactions should be reported to the national pharmacovigilance programme, such as the Pharmacovigilance Programme of India.

Traps

  • Dismissing early SJS as a viral exanthem or conjunctivitis because the skin signs are still subtle.
  • Missing the culprit because it was started weeks earlier, or because it was an over-the-counter or traditional remedy.
  • Restarting the suspected drug, or a closely related one, later in the admission.
  • Delaying transfer while waiting for a biopsy result.
  • Leaving the eyes until the skin has settled.
  • Children: following adult rules rather than the paediatric guideline.

Local burns-unit referral criteria, national guidelines and the availability of specialist care differ. Local protocols take precedence.

How Sana Health helps

Given the morphology, mucosal involvement, the percentage of skin detached and every medicine started in the last 8 weeks with dates, the Dermatology engine writes a Morphology Summary, builds the drug timeline against the latency of each reaction and names the likely culprit. It calculates SCORTEN with each item shown, states that the culprit should be stopped and where the patient should be cared for, and lists the supportive care and ophthalmology steps. References are read from PubMed when the question is asked.

Questions

What is the difference between SJS and TEN?

They are the same disease at different extents. Skin detachment under 10% of body surface area is SJS, 10% to 30% is SJS/TEN overlap, and over 30% is TEN. Both involve mucosae and both need urgent withdrawal of the culprit drug and specialist care.

When should SCORTEN be calculated?

Within the first 24 hours of admission and again around day 3. It uses age, malignancy, heart rate, the area detached, urea, glucose and bicarbonate, and predicts mortality. It informs, but does not decide, the place of care.

Do steroids or IVIG work in toxic epidermal necrolysis?

The evidence is uncertain. Systematic reviews, including a Cochrane review, have not established that any systemic therapy reliably reduces mortality, and practice varies between centres. Supportive care in an experienced unit remains the cornerstone, and systemic treatment is decided with the specialist team.

References

  1. Severe cutaneous adverse reactions to drugs (opens in a new tab)Lancet, 2017
  2. Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis (opens in a new tab)Clin Rev Allergy Immunol, 2018
  3. Epidermal necrolysis: 60 years of errors and advances (opens in a new tab)Br J Dermatol, 2015
  4. Diagnosing and Managing Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Adults: Review of Evidence 2017-2023 (opens in a new tab)J Invest Dermatol, 2025
  5. U.K. guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016 (opens in a new tab)Br J Dermatol, 2016
  6. Society of Dermatology Hospitalists supportive care guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults (opens in a new tab)J Am Acad Dermatol, 2020
  7. Scoring Assessments in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis (opens in a new tab)Front Med (Lausanne), 2022
  8. Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis (opens in a new tab)JAMA Dermatol, 2013
  9. Worldwide Prevalence of Antibiotic-Associated Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review and Meta-analysis (opens in a new tab)JAMA Dermatol, 2023
  10. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review of Ophthalmic Management and Treatment (opens in a new tab)Vision (Basel), 2025
  11. Systemic interventions for treatment of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome (opens in a new tab)Cochrane Database Syst Rev, 2022
  12. Systemic Immunomodulating Therapies for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review and Meta-analysis (opens in a new tab)JAMA Dermatol, 2017